Triggering and resolution of inflammation in NASH
S Schuster, D Cabrera, M Arrese… - Nature reviews …, 2018 - nature.com
Nonalcoholic steatohepatitis (NASH) is considered the progressive form of nonalcoholic fatty
liver disease (NAFLD) and is characterized by liver steatosis, inflammation, hepatocellular …
liver disease (NAFLD) and is characterized by liver steatosis, inflammation, hepatocellular …
Effects of dietary n–3 and n–6 polyunsaturated fatty acids in inflammation and cancerogenesis
KP Liput, A Lepczyński, M Ogłuszka… - International journal of …, 2021 - mdpi.com
The dietary recommendation encourages reducing saturated fatty acids (SFA) in diet and
replacing them with polyunsaturated fatty acids (PUFAs) n–3 (omega–3) and n–6 (omega …
replacing them with polyunsaturated fatty acids (PUFAs) n–3 (omega–3) and n–6 (omega …
Engineered human hepatocyte organoids enable CRISPR-based target discovery and drug screening for steatosis
D Hendriks, JF Brouwers, K Hamer, MH Geurts… - Nature …, 2023 - nature.com
The lack of registered drugs for nonalcoholic fatty liver disease (NAFLD) is partly due to the
paucity of human-relevant models for target discovery and compound screening. Here we …
paucity of human-relevant models for target discovery and compound screening. Here we …
Arachidonic acid metabolites in cardiovascular and metabolic diseases
T Sonnweber, A Pizzini, M Nairz, G Weiss… - International journal of …, 2018 - mdpi.com
Lipid and immune pathways are crucial in the pathophysiology of metabolic and
cardiovascular disease. Arachidonic acid (AA) and its derivatives link nutrient metabolism to …
cardiovascular disease. Arachidonic acid (AA) and its derivatives link nutrient metabolism to …
Bioactive lipid species and metabolic pathways in progression and resolution of nonalcoholic steatohepatitis
G Musso, M Cassader, E Paschetta, R Gambino - Gastroenterology, 2018 - Elsevier
The prevalence of nonalcoholic steatohepatitis (NASH) is increasing worldwide, yet there
are no effective treatments. A decade has passed since the initial lipidomics analyses of liver …
are no effective treatments. A decade has passed since the initial lipidomics analyses of liver …
[HTML][HTML] Resolvins, specialized proresolving lipid mediators, and their potential roles in metabolic diseases
Inflammation is associated with the development of diseases characterized by altered
nutrient metabolism. Although an acute inflammatory response is host-protective and …
nutrient metabolism. Although an acute inflammatory response is host-protective and …
Lipidomic biomarkers and mechanisms of lipotoxicity in non-alcoholic fatty liver disease
G Svegliati-Baroni, I Pierantonelli, P Torquato… - Free Radical Biology …, 2019 - Elsevier
Non-alcoholic fatty liver disease (NAFLD) represents the most common form of chronic liver
disease worldwide (about 25% of the general population) and 3–5% of patients develop non …
disease worldwide (about 25% of the general population) and 3–5% of patients develop non …
[PDF][PDF] Altered hepatic gene expression in nonalcoholic fatty liver disease is associated with lower hepatic n‐3 and n‐6 polyunsaturated fatty acids
BM Arendt, EM Comelli, DWL Ma, W Lou… - …, 2015 - Wiley Online Library
In nonalcoholic fatty liver disease, hepatic gene expression and fatty acid (FA) composition
have been reported independently, but a comprehensive gene expression profiling in …
have been reported independently, but a comprehensive gene expression profiling in …
Fatty acids consumption: the role metabolic aspects involved in obesity and its associated disorders
P Silva Figueiredo, A Carla Inada, G Marcelino… - Nutrients, 2017 - mdpi.com
Obesity and its associated disorders, such as insulin resistance, dyslipidemia, metabolic
inflammation, dysbiosis, and non-alcoholic hepatic steatosis, are involved in several …
inflammation, dysbiosis, and non-alcoholic hepatic steatosis, are involved in several …
Metabolism dysregulation induces a specific lipid signature of nonalcoholic steatohepatitis in patients
Nonalcoholic steatohepatitis (NASH) is a condition which can progress to cirrhosis and
hepatocellular carcinoma. Markers for NASH diagnosis are still lacking. We performed a …
hepatocellular carcinoma. Markers for NASH diagnosis are still lacking. We performed a …